SOL-GEL TECHNOLOGIES Reports 83.2% Drop in Revenue for FY2023 Q2
August 20, 2023
🌧️Earnings Overview
SOL-GEL ($NASDAQ:SLGL):
Analysis
GoodWhale is an online platform that can be used to analyze a company’s financials. Analyzing SOL-GEL TECHNOLOGIES‘ financials through GoodWhale gives an overall risk rating of high. This indicates not only a financial risk, but also a business risk. In particular, GoodWhale has detected three risk warnings in the balance sheet, cash flow statement and financial journal. It is important to consider these risks when making an investment decision. If you would like to learn more about these risks and any others associated with investing in SOL-GEL TECHNOLOGIES, you can register on goodwhale.com to gain further insights. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sol-gel Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 1.26 | -25.88 | -2060.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sol-gel Technologies. More…
| Operations | Investing | Financing |
| -9.48 | 1.7 | 0.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sol-gel Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 55.1 | 6.81 | 1.74 |
Key Ratios Snapshot
Some of the financial key ratios for Sol-gel Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -54.5% | – | -2183.2% |
| FCF Margin | ROE | ROA |
| -768.7% | -37.1% | -31.1% |
Peers
The company’s competitors include Lipocine Inc, Immuneering Corp, Alk-Abello A/S, and other nanotechnology companies.
– Lipocine Inc ($NASDAQ:LPCN)
Lipocine Inc is a biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for men’s and women’s health. The company has a market cap of 36.65M as of 2022 and a Return on Equity of 6.7%. Lipocine’s products include Testoderm, a transdermal testosterone replacement therapy for men; Androderm, a transdermal testosterone replacement therapy for men; and Troche, a buccal testosterone replacement therapy for men.
– Immuneering Corp ($NASDAQ:IMRX)
The company’s market capitalization is 191.17M as of 2022. The company’s ROE is -23.91%. The company is engaged in the business of providing software solutions to the healthcare industry. The company’s products are used by healthcare providers to manage patient care, improve patient safety, and reduce costs. The company’s products are sold to customers in the United States, Canada, Europe, and Asia.
– Alk-Abello A/S ($BER:4AJ0)
Alk-Abello A/S is a Danish biopharmaceutical company that produces and markets pharmaceuticals for the treatment of allergy. The company was founded in 1931 and has been listed on the Copenhagen Stock Exchange since 1983. Alk-Abello A/S has a market capitalization of 3.08 billion as of 2022 and a return on equity of 6.8%. The company’s products are sold in more than 60 countries and its products are used by more than 60 million people worldwide. Alk-Abello A/S is a world leader in the research and development of allergy treatments and its products are backed by more than 80 years of scientific research.
Summary
SOL-GEL TECHNOLOGIES recently reported their latest quarterly earnings results ending June 30 2023, showing a substantial drop in both total revenue and net income. Total revenue year over year fell by 83.2% to USD 0.6 million, and net income decreased to USD -6.0 million from -0.1 million in the same period last year. From an investing perspective, these figures are concerning and suggest that investors should proceed with caution before investing in SOL-GEL TECHNOLOGIES. The company’s financials will need to be closely monitored to determine how the company plans to address these sharp declines and restore profitability.
Additionally, investors must evaluate if the company has the capacity to rebound from these declines in the future.
Related Posts
Recent Posts
